GET DAILY SIGNALSEVGO vs OCGN: Swing Trader's Guide to 14.13% and strong performance
A Comparative Analysis: EVGO vs OCGN in the Context of Swing Trading and Price Growth
Compare: Swing Trader: High Volatility Stocks for Active Trading (TA&FA) generate 14.13% for EVGO vs Swing Trader: High Volatility Stocks for Active Trading (TA&FA) generate 24.84% for OCGN
A comparative look at EVGO and OCGN reveals intriguing insights for swing traders interested in high-volatility stocks. This analysis offers a detailed comparison of the two companies, reviewing their recent performance, price growth, and forthcoming earnings reports.
High Volatility Stocks for Active Trading
Swing traders focusing on high-volatility stocks through technical analysis and fundamental analysis (TA&FA) experienced quite different results for EVGO and OCGN. Specifically, a strategy applied to EVGO, a player in the Specialty Stores industry, generated a strong performance. Conversely, the same methodology yielded a higher strong performance when applied to OCGN, a Biotechnology industry constituent.
Week-on-Week Price Growth
EVGO experienced a week-on-week price change of +14.32%, outpacing OCGN, which posted a price change of +12.12% in the same period. Notably, both stocks significantly outperformed their respective industry averages, suggesting their strong momentum relative to peers.
For context, the average weekly price change across the Specialty Stores industry was a slight drop of -0.54%, while the Biotechnology industry posted a similar contraction of -0.69%.
Longer-Term Price Growth
When expanding the horizon to longer-term performance, different trends emerge. The average monthly price growth for the Specialty Stores industry, where EVGO operates, stood at +3.39%, while the Biotechnology industry, home to OCGN, experienced a higher average growth of +4.11%.
Looking at an even broader perspective, the average quarterly price growth for the Specialty Stores industry stood at +9.72%, compared to a substantial +40.50% for the Biotechnology industry. Thus, while EVGO demonstrated stronger week-on-week growth, OCGN seems to be part of an industry experiencing more robust quarterly growth.
Upcoming Earnings Reports
Lastly, earnings reports serve as critical events that often drive substantial price swings. EVGO is expected to report earnings on August 09, 2023, while OCGN is slated to announce its earnings slightly earlier, on August 04, 2023. Swing traders often watch these dates closely, as earnings reports can trigger significant volatility, creating opportunities for outsized gains.
Both EVGO and OCGN have demonstrated strong recent performance with their respective weekly price growth outperforming their industry averages. While EVGO showed stronger week-on-week performance, OCGN, operating in the Biotechnology industry, appears to benefit from more substantial industry-wide quarterly growth. As earnings dates for both companies approach, swing traders may find further opportunities in these high-volatility stocks.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
OCGN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for OCGN turned positive on November 02, 2026. Looking at past instances where OCGN's MACD turned positive, the stock continued to rise in 50 of 55 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OCGN's RSI Indicator exited the oversold zone, 30 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 69 cases where OCGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on OCGN as a result. In 71 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +20.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where OCGN advanced for three days, in 186 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OCGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
OCGN broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for OCGN entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-17.912) is normal, around the industry mean (2.904). P/E Ratio (-3.363) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (70.423) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. OCGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development and commercialization of therapies for eye diseases
Industry Biotechnology
Advertisement